Evidence map›Paper›PMID 37514046›Full record

ArticlePharmaceutics2023

Assessment of Different Niosome Formulations for Optogenetic Applications: Morphological and Electrophysiological Effects.

José David Celdrán, Lawrence Humphreys, Desirée González, Cristina Soto-Sánchez, Gema Martínez-Navarrete, Iván Maldonado, Idoia Gallego, Ilia Villate-Beitia, Myriam Sainz-Ramos, Gustavo Puras and 2 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

José David CeldránBiomedical Neuroengineering, Institute of Bioengineering (IB), University Miguel Hernández (UMH), 03020 Elche, Spain.
Lawrence HumphreysBiomedical Neuroengineering, Institute of Bioengineering (IB), University Miguel Hernández (UMH), 03020 Elche, Spain.ORCID 0000-0003-1366-1396
Desirée GonzálezBiomedical Neuroengineering, Institute of Bioengineering (IB), University Miguel Hernández (UMH), 03020 Elche, Spain.
Cristina Soto-SánchezBiomedical Neuroengineering, Institute of Bioengineering (IB), University Miguel Hernández (UMH), 03020 Elche, Spain.ORCID 0000-0003-4447-5967
Gema Martínez-NavarreteBiomedical Neuroengineering, Institute of Bioengineering (IB), University Miguel Hernández (UMH), 03020 Elche, Spain.
Iván MaldonadoNetworking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Carlos III Health Institute (ISCIII), 28029 Madrid, Spain.
Idoia GallegoNetworking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Carlos III Health Institute (ISCIII), 28029 Madrid, Spain.ORCID 0000-0002-9312-8147
Ilia Villate-BeitiaNetworking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Carlos III Health Institute (ISCIII), 28029 Madrid, Spain.ORCID 0000-0002-3738-7611
Myriam Sainz-RamosNetworking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Carlos III Health Institute (ISCIII), 28029 Madrid, Spain.ORCID 0000-0001-7266-5771
Gustavo PurasNetworking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Carlos III Health Institute (ISCIII), 28029 Madrid, Spain.ORCID 0000-0002-1536-7601
José Luis PedrazNetworking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Carlos III Health Institute (ISCIII), 28029 Madrid, Spain.ORCID 0000-0002-3938-2267
Eduardo FernándezBiomedical Neuroengineering, Institute of Bioengineering (IB), University Miguel Hernández (UMH), 03020 Elche, Spain.ORCID 0000-0002-7052-6011
Universitat de Miguel Hernández d'Elx · ESUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene therapy and optogenetics are becoming promising tools for treating several nervous system pathologies. Currently, most of these approaches use viral vectors to transport the genetic material inside the cells, but viruses present some potential risks, such as marked immunogenicity, insertional mutagenesis, and limited insert gene size. In this framework, non-viral nanoparticles, such as niosomes, are emerging as possible alternative tools to deliver genetic material, avoiding the aforementioned problems. To determine their suitability as vectors for optogenetic therapies in this work, we tested three different niosome formulations combined with three optogenetic plasmids in rat cortical neurons in vitro. All niosomes tested successfully expressed optogenetic channels, which were dependent on the ratio of niosome to plasmid, with higher concentrations yielding higher expression rates. However, we found changes in the dendritic morphology and electrophysiological properties of transfected cells, especially when we used higher concentrations of niosomes. Our results highlight the potential use of niosomes for optogenetic applications and suggest that special care must be taken to achieve an optimal balance of niosomes and nucleic acids to achieve the therapeutic effects envisioned by these technologies.

Indexed as

electrophysiological effectsmorphological effectsniosomesoptogenetics

Identifiers

PMID37514046
PMCPMC10384779
OpenAlexW4382982326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.